Keymed Biosciences

Keymed Biosciences is a Chinese biopharmaceutical company involved in the development and licensing of antibody-based medicines. They are currently newsworthy due to the acquisition of Ouro Medicines by Gilead Sciences. Ouro Medicines was developing an antibody-based medicine for autoimmune diseases that was originally licensed from Keymed Biosciences. This deal, valued at up to US$2.18 billion, highlights the increasing trend of global pharmaceutical companies acquiring or licensing drug candidates from Chinese firms to replenish their pipelines, particularly as they face patent expirations. The increased investment from mainland Chinese investors into Hong Kong-listed drug stocks, including those tracked by the Hang Seng Southbound Connect Hong Kong Innovative Drug Index, further underscores the growing significance of Chinese pharmaceutical companies like Keymed Biosciences in the global pharmaceutical landscape.